<scp>IDH</scp>2 is a novel diagnostic and prognostic serum biomarker for non‐small‐cell lung cancer

Jiangjiang Li, Ruilei Li, Wenxiang Wang, Baihua Zhang, Xin Song, Chunfang Zhang, Yang Gao, Qianjin Liao, Ya He, Shuo You, Zheqiong Tan, Xiangjian Luo, Yueshuo Li, Min Tang, Xinxian Weng, Wei Yi, Shifang Peng, Shaohui Liu, Ying Tan, Ann M. Bode, Ya CaoMolecular 2018 · DOI

TL;DR

Researchers have identified Isocitrate Dehydrogenase 2 (IDH2) as a promising new biomarker in blood for diagnosing and predicting the prognosis of non-small-cell lung cancer (NSCLC). Elevated IDH2 levels in serum can distinguish NSCLC patients from healthy individuals and are associated with poorer survival outcomes, offering a potential improvement over current diagnostic methods.

What Problem Does This Paper Address?

Lung cancer remains a leading cause of cancer-related deaths globally, largely due to late diagnosis, which significantly impacts patient survival rates. Current diagnostic tools and biomarkers for non-small-cell lung cancer (NSCLC) have limitations in terms of specificity and effectiveness. The authors previously identified a specific genetic variant of IDH2 (rs11540478) as a risk factor for lung cancer. This study aims to investigate whether the IDH2 protein itself, detectable in serum, can serve as a novel, non-invasive biomarker for both diagnosing NSCLC and predicting patient outcomes.

Methods

The study employed a multi-pronged approach:

  • Cell Culture Experiments: Two NSCLC cell lines (H460 and A549) were cultured to assess IDH2 protein secretion. Researchers measured IDH2 levels in the culture medium over time and with increasing cell numbers to understand if and how IDH2 is released by cancer cells. They also tested other cancer cell lines (HCT116 and HT29) and the related enzyme IDH1 to assess the specificity of this phenomenon.
  • ELISA (Enzyme-Linked Immunosorbent Assay): This standard laboratory technique was used to quantify IDH2 protein levels in serum samples.
  • Patient Cohort Analysis: Serum samples from a large cohort of NSCLC patients and healthy controls were analyzed using ELISA. The cohort was divided into training and testing sets to validate findings.
  • Statistical Analysis:
    • ROC (Receiver Operating Characteristic) Curve Analysis: Used to evaluate the diagnostic accuracy of serum IDH2 levels in distinguishing NSCLC patients from healthy controls. The Area Under the Curve (AUC) was a key metric.
  • Mann-Whitney U-test: Employed to compare IDH2 levels between different groups (e.g., NSCLC patients vs. controls, different cancer subtypes).
  • Kaplan-Meier Survival Analysis: Used to assess the association between serum IDH2 levels and patient survival rates.
  • Cox Regression Analysis: Utilized to identify independent prognostic factors for overall survival.

Datasets

The study utilized serum samples from:

  • 296 patients with NSCLC: Recruited from Xiangya Hospital, Kunming Medical University, and Hunan Cancer Hospital between 2013 and 2017. These samples were further divided into a training set (96 patients) and a test set (200 patients).
  • 380 healthy control subjects: Recruited from Xiangya Hospital and Kunming Medical University. These were also divided into training (130) and test (250) sets.
  • 29 paired pre- and post-surgical NSCLC patient samples: Collected to assess the impact of tumor removal on serum IDH2 levels.

No new benchmarks were introduced; the study focused on evaluating a potential new biomarker using established techniques and patient data.

Key Insights and Ideas

  • IDH2 Protein Secretion by Cancer Cells: The finding that IDH2 protein is elevated in the culture medium of NSCLC cells suggests that cancer cells actively release this protein. This is a crucial insight, as it provides a biological basis for detecting IDH2 in bodily fluids like serum.
  • Serum IDH2 as a Diagnostic Tool: The study demonstrates that serum IDH2 levels can effectively differentiate NSCLC patients from healthy individuals, with a notable AUC of 0.83. This suggests IDH2 has potential as a non-invasive diagnostic marker, potentially complementing or improving upon existing methods.
  • IDH2 Levels Decrease Post-Surgery: The observation that serum IDH2 levels decrease after surgical removal of the tumor further supports its association with the presence of cancer. This decline suggests that the tumor itself is a significant source of circulating IDH2.
  • Prognostic Value of Serum IDH2: Perhaps the most impactful finding is that higher serum IDH2 levels are correlated with poorer overall survival in NSCLC patients. This positions IDH2 not just as a diagnostic marker but also as a valuable prognostic tool, helping to stratify patients by risk.

Key Results

  • Cell Culture: IDH2 protein levels in the culture medium of NSCLC cells increased in a time- and cell number-dependent manner. This was also observed in colon cancer cell lines, suggesting it's not exclusive to NSCLC.
  • Diagnostic Accuracy: Serum IDH2 levels could distinguish NSCLC patients from healthy controls with an AUC of 0.83 (95% CI = 0.79-0.88). This performance was comparable to or better than some existing biomarkers.
  • Post-Surgical Levels: IDH2 levels in serum were significantly lower in NSCLC patients one week after surgery compared to their pre-surgical levels, and approached levels seen in healthy controls.
  • Prognostic Significance: Kaplan-Meier survival analysis showed that patients with high serum IDH2 levels had significantly worse overall survival rates (P = 0.042).

Limitations and Future Work

  • Specificity: While IDH2 showed promise, the study acknowledges that some overlap in IDH2 levels was observed between NSCLC patients and healthy controls. Further research is needed to determine if serum IDH2 is specific to NSCLC or if it can be used as an adjunctive biomarker alongside others.
  • Mechanism of Secretion: The exact mechanism by which IDH2 is secreted into the extracellular space and then into the serum is not fully elucidated. The authors suggest it could be through exosomes or other cellular processes.
  • Broader Application: The study focused on NSCLC. Future work could explore whether serum IDH2 is a useful biomarker for other cancer types.
  • Clinical Validation: While the study used a substantial cohort, larger, multi-center prospective studies would be beneficial to further validate these findings and establish IDH2 as a reliable clinical biomarker.
  • Comparison with Other Biomarkers: While the AUC was reported, a direct head-to-head comparison with a panel of established NSCLC biomarkers in a single study would strengthen the argument for IDH2's superiority or complementary role.

Summary updated

Abstract

Lung cancer is the most common leading cause of cancer-related death worldwide. Late diagnosis contributes to a high mortality rate and poor survival of this cancer. In our previous study, we found that IDH2 polymorphism rs11540478 is a risk factor for lung cancer. Here, we examined IDH2 protein expression in culture medium in which two non-small-cell lung cancer (NSCLC) cell lines, H460 and A549, were growing. We found that the IDH2 protein was elevated in the culture supernatant fraction in a time- and cell number-dependent manner. Next, we used ELISA methods to examine IDH2 protein level in serum from patients with NSCLC and healthy controls. We found that IDH2 protein levels in serum could distinguish NSCLC patients from healthy controls with an AUC (area under the curve) of 0.83 (95% confidence interval = 0.79-0.88). The IDH2 level was decreased in serum from NSCLC postsurgical patients compared with the paired presurgical serum. High serum IDH2 levels appear to correlate with poor survival in patients with NSCLC. These results suggest that IDH2 levels in the serum could be a new effective biomarker for the diagnosis and prognosis of NSCLC.
BibTeX
@inproceedings{li2018scp,
  author = {Jiangjiang Li and Ruilei Li and Wenxiang Wang and Baihua Zhang and Xin Song and Chunfang Zhang and Yang Gao and Qianjin Liao and Ya He and Shuo You and Zheqiong Tan and Xiangjian Luo and Yueshuo Li and Min Tang and Xinxian Weng and Wei Yi and Shifang Peng and Shaohui Liu and Ying Tan and Ann M. Bode and Ya Cao},
  title = {{<scp>IDH</scp>2 is a novel diagnostic and prognostic serum biomarker for non‐small‐cell lung cancer}},
  booktitle = {Molecular},
  year = {2018},
  doi = {10.1002/1878-0261.12182},
}
Figure